Brief: Strides Pharma Science Receives USFDA EIR For Flagship Facility In Bengaluru
19/08/2026 16:35
BRIEF-Strides Pharma Science Receives USFDA EIR For Flagship Facility In Bengaluru Aug 19 (Reuters) - Strides Pharma Science Ltd SRID.NS:
RECEIVES USFDA EIR FOR FLAGSHIP FACILITY IN BENGALURU
USFDA HAS CLASSIFIED INSPECTION OUTCOME AS VOLUNTARY ACTION INDICATED
Source text: ID:nBSE8GDFLM
Further company coverage: SRID.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Strides Pharma Science
See all newsIndia's Strides Pharma jumps on successful closure of USFDA inspection at Bengaluru facility
Brief: Strides Pharma Science Receives USFDA EIR For Flagship Facility In Bengaluru
Brief: Strides Pharma Science Receives US FDA Establishment Inspection Report For Bengaluru Facility
Brief: Strides Pharma Science June-Quarter Consol Net Profit 1.57 Billion Rupees
Brief: Strides Pharma Science March-Quarter Consol Net Profit 1.27 Billion Rupees